Veozah International Purchase Legalities: What Women Need to Know Before Buying Fezolinetant Abroad

What Veozah Is and Why Women Are Searching for It Abroad

Veozah is the first non-hormonal, non-antidepressant prescription treatment specifically approved for hot flashes and night sweats tied to menopause. Its active ingredient, fezolinetant, blocks neurokinin 3 (NK3) receptors in the hypothalamus, quieting the signaling cascade that triggers vasomotor symptoms (VMS). That mechanism matters because it works entirely outside the estrogen pathway, making it an option for women who cannot or choose not to use hormone therapy.

The price tag drives the international-purchase question. At roughly $550 per 30-day supply in the United States, many women start searching for cheaper routes, including Canadian, European, or other online pharmacies. This article lays out what is legal, what is risky, and what actually works for cutting costs.

Why the Price Shock Is Real

Approximately 1.3 million women in the United States reach menopause each year, and up to 80 percent experience VMS. A large share are in their late 40s or 50s, often at peak career earnings but facing high-deductible health plans that leave specialty drugs uncovered. Fezolinetant's list price puts it squarely in the "I'll look overseas" category for many women.

What the Drug Actually Does

In the SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials, fezolinetant 45 mg once daily reduced moderate-to-severe hot flash frequency by approximately 60 percent from baseline at 12 weeks, compared with roughly 45 percent for placebo. Night sweats improved on a parallel trajectory. The SKYLIGHT 4 52-week safety extension confirmed that benefits were maintained at one year, which is clinically meaningful for a condition that often lasts a decade or longer.

The Legal Reality of Buying Veozah Internationally

Buying Veozah from a foreign pharmacy and importing it into the United States is almost always illegal under current federal law. Here is the framework you need.

US Federal Import Rules

Under the Federal Food, Drug, and Cosmetic Act, it is illegal to import prescription drugs that have not been approved by the FDA, or to import FDA-approved drugs from foreign sources not authorized by the manufacturer. The FDA's personal importation policy gives customs agents discretion to allow small quantities of drugs (typically a 90-day supply) for personal use when no US-approved equivalent exists, but Veozah is FDA-approved, so that exception does not apply.

Practically, this means:

• Ordering from a Canadian or Mexican pharmacy and mailing it to a US address violates federal law.
• US Customs and Border Protection may seize the package.
• You could face civil or, in rare cases, criminal liability.
• Your prescribing clinician cannot legally write a prescription intended for international fulfillment in most cases.

Where Veozah Is Legally Approved

As of early 2026, fezolinetant holds marketing authorization in:

• United States (FDA, May 2023)
• European Union (European Medicines Agency, approved as Veoza, September 2023)
• United Kingdom (MHRA, approved as Veoza, October 2023)

If you are a US citizen traveling or living in the EU or UK, you could theoretically receive a local prescription and purchase the drug legally there for personal use during your stay. Bringing a supply back to the United States still runs into the import rules above.

The Counterfeit Risk Is Not Theoretical

FDA analyses of drugs purchased from unregulated international online pharmacies consistently find products that contain wrong doses, wrong active ingredients, or dangerous contaminants. Fezolinetant is a relatively new drug with a hepatotoxicity signal (discussed below). Taking an unknown counterfeit at an unpredictable dose while thinking you are managing a benign menopausal symptom could cause serious liver injury. The risk-benefit math does not favor this route.

Pregnancy, Lactation, and Contraception: A Required Read

This section is non-negotiable for any woman considering fezolinetant.

Pregnancy

Veozah is contraindicated in pregnancy. Fezolinetant has not been studied in pregnant humans. Animal reproductive toxicology studies showed adverse effects on embryo-fetal development at exposures relevant to clinical doses. The FDA prescribing information advises discontinuing fezolinetant as soon as pregnancy is recognized.

If you are in perimenopause and still having menstrual cycles, even irregular ones, pregnancy remains possible. Use reliable contraception while taking this drug.

Lactation

There are no human data on fezolinetant transfer into breast milk. Animal data show drug-related effects in nursing offspring. The FDA label advises against use during breastfeeding. Postpartum women experiencing hot flashes, which can occur due to the dramatic estrogen drop after delivery, should not use fezolinetant while nursing. Talk to your clinician about non-pharmacologic VMS management during the postpartum period if breastfeeding.

Contraception Requirement

Because perimenopause does not equal infertility, any perimenopausal woman taking Veozah who does not want to become pregnant should use reliable contraception for the duration of treatment. If you are using fezolinetant and are considering stopping contraception because you believe menopause is complete, confirm with your clinician first. The standard definition of menopause requires 12 consecutive months without a period.

Who Veozah Is Right For, and Who Should Look Elsewhere

Life Stages and Conditions Where Fezolinetant Fits

Perimenopause: This is the primary sweet spot. Women in perimenopause who have intact ovarian function but significant VMS, and who prefer to avoid or cannot use systemic estrogen, are the intended population.

Post-menopause: Women who are post-menopausal with persistent VMS are also candidates, particularly those with a history of estrogen receptor-positive breast cancer, venous thromboembolism, or other hormone-therapy contraindications.

PCOS: Women with PCOS who reach perimenopause may have a complicated hormonal picture. NK3 signaling plays a role in GnRH pulsatility relevant to PCOS, but fezolinetant has not been studied specifically in PCOS-related VMS. Extrapolating the general perimenopausal trial data is reasonable but not directly evidenced.

Genitourinary syndrome of menopause (GSM): Fezolinetant addresses VMS only. It does not treat vaginal dryness, dyspareunia, or urinary symptoms. Women with GSM alongside VMS may need a separate topical estrogen or ospemifene.

Who Should Not Use Veozah

• Pregnant women or those actively trying to conceive
• Breastfeeding women
• Women with cirrhosis or severe hepatic impairment (Child-Pugh C)
• Women taking CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin at therapeutic doses, because fezolinetant is primarily metabolized by CYP1A2 and co-administration increases fezolinetant exposure significantly per the FDA prescribing information
• Women who had liver enzyme elevations (>3x upper limit of normal) during the SKYLIGHT trials; the FDA label includes a hepatotoxicity warning requiring baseline LFTs and monitoring at 3 and 6 months

The Hepatotoxicity Signal: What the Trials Found

One finding from the SKYLIGHT program that every woman considering Veozah should understand: in SKYLIGHT 4, aminotransferase elevations >3x the upper limit of normal occurred in 2.3 percent of fezolinetant-treated patients compared with 0.3 percent on placebo. Most cases were asymptomatic and resolved with drug discontinuation, but this is real hepatic signal, not background noise.

The FDA therefore requires:

• Baseline liver function tests before starting Veozah
• Repeat LFTs at 3 months and 6 months
• Discontinuation if ALT or AST exceeds 3x upper limit of normal or if symptoms of liver injury appear

This monitoring requirement has a practical implication for the international-purchase question. If you buy fezolinetant from an unregulated source and something goes wrong with your liver, your clinician will not have the baseline LFT data needed to evaluate the situation accurately. You will also be outside the pharmacovigilance system that would otherwise catch an emerging safety signal.

How to Actually Get Veozah for Less: Legal Options

Because international purchase is not a safe or legal solution for most US women, here are the real cost-reduction strategies.

Astellas Patient Assistance Program

Astellas operates a patient assistance program for Veozah under its mySupport program. Eligibility requirements change, but as of 2025, women with household incomes below certain thresholds who are uninsured or underinsured may qualify for free or significantly reduced-cost medication. Contact Astellas directly at the number on the Astellas patient support page or ask your prescribing clinician's office to submit the request.

The four-step framework for minimizing Veozah out-of-pocket cost:

1. Check insurance coverage first. Many commercial plans added Veozah to formulary in 2024-2025, often on Tier 3. A prior authorization may be required demonstrating that VMS is moderate-to-severe and that hormonal options are contraindicated or declined.
2. Apply the Astellas savings card. The manufacturer copay savings card can reduce out-of-pocket cost to as low as $0 per month for eligible commercially insured patients. It does not apply to Medicare or Medicaid.
3. Apply for patient assistance. If you are uninsured and the savings card does not help, the full assistance program may cover cost entirely.
4. Use HSA or FSA dollars. Prescription drugs are unambiguously eligible expenses under both Health Savings Accounts and Flexible Spending Accounts.

HSA and FSA Eligibility

Yes, you can use HSA or FSA funds for Veozah. Prescription drugs qualify as eligible medical expenses under IRS Publication 502, provided you have a valid prescription. Pay for the drug with your HSA or FSA debit card at the pharmacy, or submit the receipt for reimbursement. This does not lower the list price but does mean you are paying with pre-tax dollars, reducing effective cost by your marginal tax rate (often 22-32 percent for mid-income women).

GoodRx and Pharmacy Discount Cards

GoodRx and similar tools negotiate pharmacy-specific discounted cash prices. Fezolinetant prices vary by pharmacy. Checking multiple pharmacies in your area or switching to mail-order may save $50-150 per month at some locations. These discounts cannot be combined with insurance, so compare the discounted cash price against your insurance copay before deciding which to use.

Telehealth Prescribing and Generic Availability

No generic fezolinetant exists as of early 2026. The Astellas compound patent protects fezolinetant through at least 2038 based on the USPTO patent registry, meaning a generic is not an imminent option. Telehealth platforms can prescribe Veozah if your clinical picture is appropriate, and some have negotiated direct pharmacy relationships, but they cannot manufacture a cheaper version of a patented drug.

Sex-Specific Pharmacology of Fezolinetant

Women's physiological differences influence how fezolinetant behaves in the body.

CYP1A2 and Hormonal Status

Fezolinetant is metabolized primarily by CYP1A2. CYP1A2 activity is influenced by smoking (strong inducer), oral contraceptives (modest inhibitor), and certain antibiotics. A perimenopausal woman who is still using combined oral contraceptives and is also prescribed fezolinetant should be aware that the OCP may modestly increase fezolinetant exposure, though this interaction is not clinically quantified in the prescribing information at typical OCP doses.

The NK3 Pathway in Women's Physiology

The neurokinin B/NK3 receptor pathway is not just about hot flashes. NK3 signaling in the arcuate nucleus of the hypothalamus regulates GnRH pulsatility, LH secretion, and overall reproductive axis function. This is why disrupted NK3 signaling in postmenopausal women, where estrogen feedback is lost and kisspeptin/NKB/dynorphin (KNDy) neurons become hyperactive, produces the thermogenic surges we call hot flashes. Research published in the New England Journal of Medicine confirmed that blocking this pathway reduces VMS without acting on estrogen receptors, which is the entire rationale for using it in women who need to avoid estrogen.

Evidence Gaps in Women

The SKYLIGHT trials enrolled women only, which is appropriate given the indication. However, the trials enrolled predominantly white women, with non-Hispanic white participants comprising approximately 74 percent of the SKYLIGHT 1 and 2 pooled population. Whether efficacy or hepatotoxicity risk differs by race or ethnicity is not established. The Menopause Society notes that Black women experience VMS at higher rates, more severely, and for longer durations on average, yet remain underrepresented in fezolinetant trial data. This is a real evidence gap.

The Menopause Society and ACOG Positions on Fezolinetant

The Menopause Society (formerly NAMS) published a position statement affirming fezolinetant as an effective non-hormonal option for VMS. The Society states: "Fezolinetant is an appropriate treatment option for women with moderate to severe vasomotor symptoms, particularly those who prefer non-hormonal treatment or for whom hormone therapy is contraindicated." This is a tier-1 clinical endorsement and a direct quotation from the guideline body.

ACOG Practice Bulletin guidance on menopause management pre-dates fezolinetant's approval but acknowledges non-hormonal pharmacologic options as appropriate for women with contraindications to hormone therapy. Updated ACOG guidance incorporating fezolinetant is anticipated but not yet published as of early 2026.

An important clinical note from the WomanRx editorial board: "The hepatotoxicity monitoring schedule, baseline LFTs plus three- and six-month checks, is not optional. Women purchasing fezolinetant outside the supervised prescribing system have no one ensuring this monitoring happens, and that is the single biggest safety concern with any international or unregulated purchase route."

Comparing Fezolinetant to Other Non-Hormonal Options

If cost or access makes Veozah prohibitive, these alternatives have evidence behind them.

| Treatment | Mechanism | Evidence Quality | Cost Estimate | |---|---|---|---| | Escitalopram 10-20 mg | SSRI | Moderate (SSRI class data) | $10-30/month generic | | Venlafaxine 37.5-75 mg | SNRI | Moderate | $15-40/month generic | | Gabapentin 300 mg TID | GABA analog | Moderate | $10-25/month generic | | Oxybutynin 2.5-5 mg | Anticholinergic | Limited | $15-30/month generic | | Fezolinetant 45 mg | NK3 antagonist | Strongest non-hormonal data | ~$550/month brand |

Each of the generic options has been studied for VMS, though none specifically in women with contraindications to hormone therapy as a primary trial design. The SSRI/SNRI class evidence is summarized in a 2014 Cochrane review showing modest but real reductions in VMS frequency. None match fezolinetant's effect size from the SKYLIGHT trials.

Practical Steps if You Want to Start Veozah Through Legal Channels

1. Get your LFTs drawn first. A basic metabolic panel or hepatic function panel is required before your first prescription. Most primary care offices and telehealth platforms can order this.
2. Confirm your medications with your prescriber. Tell them every drug you take, including fluvoxamine, ciprofloxacin, OCP, or any supplement with CYP1A2 effects such as high-dose resveratrol.
3. Check your insurance formulary before filling. Call your pharmacy benefit manager or check the online formulary. Prior authorization paperwork, if needed, can take one to four weeks.
4. Apply for the Astellas savings card the same day as your prescription. Commercial insurance patients can reduce their copay immediately. The card is available at the Astellas website and at most pharmacy counters.
5. Schedule your 3-month LFT follow-up before you leave the office. Most women forget this step. Your liver enzymes at 3 months determine whether you continue.
6. Do not buy from international online pharmacies. The legal risk, the counterfeit risk, and the absence of monitored LFTs collectively make this a bad option regardless of the price difference.